Vertex buys in on Stablix's protein stabilization approach in research and licensing deal

Nicole DeFeudis

Editor

Roughly two years after Stablix embarked on a mission to stabilize certain proteins whose insufficiency leads to disease, Vertex Pharmaceuticals announced it’s coming along for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Vertex buys in on Stablix's protein stabilization approach in research and licensing deal

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Ver­tex buys in on Sta­blix's pro­tein sta­bi­liza­tion ap­proach in re­search and li­cens­ing deal

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Vertex buys in on Stablix's protein stabilization approach in research and licensing deal